ALXO - Company ID 0001810182
The table below shows ALX ONCOLOGY HOLDINGS INC's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$18.65M | -$24.66M | -$37.92M | -$27.82M | -$20.67M | -$5.13M |
| Capital expenditure | $50.00K | $60.00K | $148.00K | $690.00K | $589.00K | $7.00K |
| Investing cash flow | -$105.04M | $27.64M | $26.47M | $42.30M | -$183.92M | -$7.00K |
| Dividends paid | - | - | - |
ALX ONCOLOGY HOLDINGS INC reported operating cash flow of -$84.14M for fiscal year 2025. That is up 31.0% from -$121.91M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$13.19M (FY 2018) to -$84.14M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $139.59M | $65.00K | $3.09M | -$107.00K | $80.00K | $778.00K |